Cowen Maintains Outperform On Agios Pharmaceuticals As AG-221 Moving In On Pivotal Trials
Cowen analyst Eric Schmidt maintained an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO), as the company announced new data from its ongoing phase 1 trial of AG-221, showing robust clinical activity in patients with advanced hematologic malignancies. No price target was provided.
Schmidt noted, “AG-221 continues to show impressive efficacy, with ORR of 56% and a duration of response of up to 8 months and running. A global registration program for AG-221 in IDH2-mutant AML to begin in 2015. Agios will host an investor luncheon today that will feature additional details on AG-221 and AG-348 for PKD.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Eric Schmidt has a total average return of 34.6% and a 80.0% success rate. Schmidt has a 106.0% average return when recommending AGIO, and is ranked #42 out of 3401 analysts.